Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 1/20 | 0.47 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.47 |
| ▸ | NPC1 | O15118 | 2/20 | 0.46 |
| ▸ | RAB9A | P51151 | 2/20 | 0.46 |
| ▸ | CASP3 | P42574 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.46 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.46 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.46 |
| ▸ | CA12 | O43570 | 2/20 | 0.46 |
| ▸ | CA1 | P00915 | 2/20 | 0.46 |
| ▸ | CA2 | P00918 | 2/20 | 0.46 |
| ▸ | CA7 | P43166 | 2/20 | 0.46 |
| ▸ | PDK2 | Q15119 | 2/20 | 0.46 |
| ▸ | CA9 | Q16790 | 2/20 | 0.46 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.46 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.46 |
| ▸ | SOS1 | Q07889 | 1/20 | 0.45 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.45 |
| ▸ | F2R | P25116 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL612915 | 0.85 | SLC6A4 (0.47) | SLC6A4SLC6A3NPC1RAB9ACASP3 | |
| SCHEMBL2708451 | 0.82 | SLC6A4 (0.51) | SLC6A4SLC6A3NPC1RAB9ACASP3 | |
| SCHEMBL30301996 | 0.82 | SLC6A4 (0.51) | SLC6A4SLC6A3NPC1RAB9ACASP3 | |
| SCHEMBL29280613 | 0.82 | CES2 (0.44) | NPC1RAB9ASMN1; SMN2F2RPKM | |
| SCHEMBL3839211 | 0.81 | NR4A2 (0.54) | SLC6A3SMN1; SMN2CA12CA1CA2 | |
| SCHEMBL523258 | 0.81 | CES2 (0.61) | SLC6A4SLC6A3NPC1RAB9ACASP3 | |
| SCHEMBL14012584 | 0.81 | CES2 (0.61) | SLC6A4SLC6A3NPC1RAB9ACASP3 | |
| SCHEMBL5777608 | 0.81 | TSHR (0.55) | CASP3SMN1; SMN2SENP7CA12CA1 | |
| SCHEMBL1578885 | 0.81 | GABRA1 (0.43) | NPC1RAB9ACA12CA1CA2 | |
| SCHEMBL31582781 | 0.80 | F2R (0.44) | NPC1RAB9ASMN1; SMN2FFAR4F2R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 613 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116854631-B | 4-Aryl-2-pyridone compound and preparation method thereof | 安徽中医药大学 | 2025-04-15 | — | — | CN | claimed |
| CN-116854631-A | 4-aryl-2-pyridone compound and preparation method thereof | 安徽中医药大学 | 2023-10-10 | — | — | CN | claimed |
| US-11465970-B2 | Method for synthesis of Roxadustat and intermediate compounds thereof | Nanjing Cavendish Bio-Engineering Tech. Co., LTD. (CN) | 2022-10-11 | — | — | US | claimed |
| EP-3712130-B1 | METHOD FOR SYNTHESIS OF ROXADUSTAT AND INTERMEDIATE COMPOUNDS THEREOF | NANJING CAVENDISH BIO ENGINEERING TECH CO LTD (CN) | 2022-08-03 | — | — | EP | claimed |
| US-20200385355-A1 | METHOD FOR SYNTHESIS OF ROXADUSTAT AND INTERMEDIATE COMPOUNDS THEREOF | Nanjing Cavendish Bio-Engineering Technology Co., Ltd. (CN) | 2020-12-10 | — | — | US | claimed |
| EP-3712130-A1 | METHOD FOR SYNTHESIS OF ROXADUSTAT AND INTERMEDIATE COMPOUNDS THEREOF | Nanjing Cavendish Bio-Engineering Technology Co., Ltd. (CN) | 2020-09-23 | — | — | EP | claimed |
| EP-3305769-B1 | METHOD FOR PREPARATION OF (7-PHENOXY-4-HYDROXY-1-METHYL-ISOQUINOLINE-3-CARBONYL)-GLYCINE (ROXEDUSTAT) AND ITS INTERMEDIATES BASED ON SIMULTANEOUS OPENING OF OXAZOLIC RING, FISSION OF ETHER AND CREATION OF IMINE | ZENTIVA KS (CZ) | 2019-06-26 | — | — | EP | claimed |
| EP-3305769-A1 | METHOD FOR PREPARATION OF (7-PHENOXY-4-HYDROXY-1-METHYL-ISOQUINOLINE-3-CARBONYL)-GLYCINE (ROXEDUSTAT) AND ITS INTERMEDIATES BASED ON SIMULTANEOUS OPENING OF OXAZOLIC RING, FISSION OF ETHER AND CREATION OF IMINE | Zentiva K.S. (CZ) | 2018-04-11 | — | — | EP | claimed |
| US-20260115296-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF RAPIDLY ACCELERATED FIBROSARCOMA POLYPEPTIDES | UNIV YALE (US) | 2026-04-30 | — | — | US | disclosed |
| US-20260109716-A1 | CEREBLON-BASED KRAS DEGRADING PROTACS AND USES RELATED THERETO | ARVINAS OPERATIONS, INC. (US) | 2026-04-23 | — | — | US | disclosed |
| US-20260085066-A1 | LEUCINE RICH REPEAT KINASE 2 (LRRK2) DEGRADING COMPOUNDS AND ASSOCIATED METHODS OF USE | ARVINAS OPERATIONS INC (US) | 2026-03-26 | — | — | US | disclosed |
| US-12583853-B2 | 1H-pyrrolo[2,3-b]pyridine derivatives and related compounds as BCL-2 inhibitors for the treatment of neoplastic and autoimmune diseases | NEWAVE PHARMACEUTICAL INC. (US) | 2026-03-24 | — | — | US | disclosed |
| US-12551490-B2 | Heterocyclic modulators of lipid synthesis | SAGIMET BIOSCIENCES INC. (US) | 2026-02-17 | — | — | US | disclosed |
| US-12552784-B2 | 1H-pyrrolo[2,3-b]pyridine derivatives as BCL-2 inhibitors for the treatment of neoplastic and autoimmune diseases | NEWAVE PHARMACEUTICAL INC. (US) | 2026-02-17 | — | — | US | disclosed |
| EP-0070389-B1 | 2-(2-FLUORO-4-HALO-5-SUBSTITUTED PHENYL) HYDANTOINS, AND THEIR PRODUCTION AND USE | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 1985-10-02 | — | — | EP | disclosed |
| US-4537892-A | ANTIDIABETIC AGENTS | ALCON LABORATORIES, INC. (US) | 1985-08-27 | — | — | US | disclosed |
| EP-0137333-A2 | Spiro-tricyclicaromatic succinimide derivatives as inhibitors of aldose reductase | ALCON LABORATORIES, INC. (US) | 1985-04-17 | — | — | EP | disclosed |
| US-4452981-A | HERBICIDES | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 1984-06-05 | — | — | US | disclosed |
| US-4437877-A | HERBICIDES | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 1984-03-20 | — | — | US | disclosed |
| EP-0075267-A1 | 4-(2-Fluoro-4-halo-5-substituted phenyl)urazols, and their production and use | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 1983-03-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200385355-A1 | METHOD FOR SYNTHESIS OF ROXADUSTAT AND INTERMEDIATE COMPOUNDS THEREOF | GNMT, XDH, AGXT | SLC6A4 373/4885SLC6A3 644/4885NPC1 2783/4885 |
| US-11465970-B2 | Method for synthesis of Roxadustat and intermediate compounds thereof | AGXT, GNMT, XDH | SLC6A4 369/4885SLC6A3 663/4885NPC1 2676/4885 |
| US-12551490-B2 | Heterocyclic modulators of lipid synthesis | FASN, FADS1, FADS2 | SLC6A4 1499/4885SLC6A3 3310/4885NPC1 89/4885 |
| US-12583853-B2 | 1H-pyrrolo[2,3-b]pyridine derivatives and related compounds as BCL-2 inhibitors for the treatment of neoplastic and autoimmune diseases | BCL3, BCL9, BCL6 | SLC6A4 3134/4885SLC6A3 2249/4885NPC1 1239/4885 |
| US-20260109716-A1 | CEREBLON-BASED KRAS DEGRADING PROTACS AND USES RELATED THERETO | KRAS, CRBN, HRAS | SLC6A4 4735/4885SLC6A3 3843/4885NPC1 2586/4885 |
| US-20260115296-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF RAPIDLY ACCELERATED FIBROSARCOMA POLYPEPTIDES | CRBN, VHL, ADRM1 | SLC6A4 4471/4885SLC6A3 4069/4885NPC1 3368/4885 |
| US-12552784-B2 | 1H-pyrrolo[2,3-b]pyridine derivatives as BCL-2 inhibitors for the treatment of neoplastic and autoimmune diseases | BCL3, BCL2A1, BCL6 | SLC6A4 4701/4885SLC6A3 3184/4885NPC1 1689/4885 |
| US-20260085066-A1 | LEUCINE RICH REPEAT KINASE 2 (LRRK2) DEGRADING COMPOUNDS AND ASSOCIATED METHODS OF USE | LRRK2, PARK7, NEDD4 | SLC6A4 1744/4885SLC6A3 485/4885NPC1 1981/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.